文献速递临床试验与 GCP

4%白蛋白溶液与醋酸林格液对体外循环心脏手术患者主要不良事件的影响:一项随机临床试验

Effect of 4% Albumin Solution vs Ringer Acetate on Major Adverse Events in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

该随机双盲单中心临床试验在2017至2020年纳入接受体外循环心脏手术的患者,比较4%白蛋白溶液与醋酸林格液作为预充液和围术期静脉容量替代液的效果。主要终点为至少发生1次主要不良事件(死亡、心肌损伤、急性心力衰竭、再开胸、卒中、心律失常、出血、感染或急性肾损伤)。白蛋白组257/693例(37.1%)发生主要不良事件,林格组234/693例(33.8%),相对危险度1.10(95%CI 0.95-1.27;P=0.20),差异无统计学意义。

要点

  • 4%白蛋白组主要不良事件发生率为37.1%,醋酸林格液组为33.8%,差异无统计学意义。
  • 相对危险度1.10(95%CI 0.95-1.27;P=0.20),绝对差异3.3个百分点(95%CI -1.7至8.4)。
  • 研究结论不支持在该场景中使用4%白蛋白溶液。

核心结论

  • 在体外循环心脏手术患者中,与醋酸林格液相比,使用4%白蛋白溶液作为预充液和围术期静脉容量替代液并未显著降低90天内主要不良事件风险。
  • 这些发现不支持在该场景中使用4%白蛋白溶液。

研究设计与样本

  • 随机双盲单中心临床试验,在三级大学医院开展,时间为2017至2020年,术后随访90天。
  • 纳入接受体外循环下冠状动脉旁路移植术、主动脉瓣/二尖瓣/三尖瓣手术、不合并低温循环停跳的升主动脉手术和/或迷宫手术的患者。
  • 共随机1407例,1386例(99%)完成试验;平均年龄65.4岁(SD 9.9),男性1091例(79%),女性295例(21%)。
  • 患者按1:1比例随机接受4%白蛋白溶液(n=693)或醋酸林格液(n=693),作为体外循环预充液及术中至术后24小时内的静脉容量替代液。

主要发现

  • 白蛋白组研究液体用量中位数2150 mL(IQR 1598-2700 mL),林格组为3298 mL(IQR 2669-3500 mL)。
  • 至少发生1次主要不良事件的患者在白蛋白组为257/693例(37.1%),在林格组为234/693例(33.8%);相对危险度(白蛋白/林格)1.10(95%CI 0.95-1.27;P=0.20),绝对差异3.3个百分点(95%CI -1.7至8.4)。
  • 最常见严重不良事件:肺栓塞白蛋白组11例(1.6%)vs 林格组8例(1.2%);心包切开术后综合征两组各9例(1.3%);需重症监护或再入院的胸腔积液白蛋白组7例(1.0%)vs 林格组9例(1.3%)。

关键数值与推荐

  • 主要终点为至少发生1次主要不良事件:死亡、心肌损伤、急性心力衰竭、再开胸、卒中、心律失常、出血、感染或急性肾损伤。

临床怎么用

  • 原文结论指出,这些发现不支持在体外循环心脏手术中采用4%白蛋白溶液进行预充和围术期静脉容量替代。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In cardiac surgery, albumin solution may maintain hemodynamics better than crystalloids and reduce the decrease in platelet count and excessive fluid balance, but randomized trials are needed to compare the effectiveness of these approaches in reducing surgical complications. OBJECTIVE: To assess whether 4% albumin solution compared with Ringer acetate as cardiopulmonary bypass prime and perioperative intravenous volume replacement solution reduces the incidence of major perioperative and postoperative complications in patients undergoing cardiac surgery. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, single-center clinical trial in a tertiary university hospital during 2017-2020 with 90-day follow-up postoperatively involving patients undergoing on-pump coronary artery bypass grafting; aortic, mitral, or tricuspid valve surgery; ascending aorta surgery without hypothermic circulatory arrest; and/or the maze procedure were randomly assigned to 2 study groups (last follow-up was April 13, 2020). INTERVENTIONS: The patients received in a 1:1 ratio either 4% albumin solution (n = 693) or Ringer acetate solution (n = 693) as cardiopulmonary bypass priming and intravenous volume replacement intraoperatively and up to 24 hours postoperatively. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of patients with at least 1 major adverse event: death, myocardial injury, acute heart failure, resternotomy, stroke, arrhythmia, bleeding, infection, or acute kidney injury. RESULTS: Among 1407 patients randomized, 1386 (99%; mean age, 65.4 [SD, 9.9] years; 1091 men [79%]; 295 women [21%]) completed the trial. Patients received a median of 2150 mL (IQR, 1598-2700 mL) of study fluid in the albumin group and 3298 mL (IQR, 2669-3500 mL) in the Ringer group. The number of patients with at least 1 major adverse event was 257 of 693 patients (37.1%) in the albumin group and 234 of 693 patients (33.8%) in the Ringer group (relative risk albumin/Ringer, 1.10; 95% CI, 0.95-1.27; P = .20), an absolute difference of 3.3 percentage points (95% CI, -1.7 to 8.4). The most common serious adverse events were pulmonary embolus (11 [1.6%] in the albumin group vs 8 [1.2%] in the Ringer group), postpericardiotomy syndrome (9 [1.3%] in both groups), and pleural effusion with intensive care unit or hospital readmission (7 [1.0%] in the albumin group vs 9 [1.3%] in the Ringer group). CONCLUSIONS AND RELEVANCE: Among patients undergoing cardiac surgery with cardiopulmonary bypass, treatment with 4% albumin solution for priming and perioperative intravenous volume replacement solution compared with Ringer acetate did not significantly reduce the risk of major adverse events over the following 90 days. These findings do not support the use of 4% albumin solution in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02560519.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Pesonen E, Vlasov H, Suojaranta R, et al. Effect of 4% Albumin Solution vs Ringer Acetate on Major Adverse Events in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized Clinical Trial. JAMA. 2022. PMID: 35852528. doi:10.1001/jama.2022.10461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。